SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”) announces that M. Faye Wilson, Board Chair, passed away unexpectedly on Monday, July 10. The Board of Directors and staff of Biocept extend their deepest condolences to the Wilson family and express their gratitude for her many contributions to Biocept.
Ms. Wilson was appointed to Biocept’s Board in 2009 and served at various times as Lead Independent Director and as Chair. Most recently, in addition to her role as Board Chair, she was a member of the Audit, Compensation, and Science and Technology Committees.
“It is with deep sadness that we announce Faye’s passing,” said Antonino Morales, Biocept President and CEO. “I had the great privilege of knowing Faye as a colleague, mentor, and friend for more than 30 years. Faye was a remarkably talented and respected business executive and philanthropist with more achievements in the business and non-profit communities than I can list here. Throughout her entire career, Faye was known as an advocate for women’s rights, diversity, and equality for all in the workplace. As an ardent supporter of Biocept, she inspired us in our quest to improve treatment choices and clinical outcomes for patients afflicted by metastatic brain cancer. She will be greatly missed.”
Ms. Wilson is survived by her sister Paula Murphy, daughter Tara Wilson, granddaughter Ivey Wilson, and great grandchildren Eydie and Ernest Noble, as well as beloved dogs Chili and Ginger. The Wilson family asks that donations in celebration of Ms. Wilson’s life be made to Helen Woodward Animal Center, The Salk Institute, or Los Angeles Opera.
Ms. Wilson was CEO of Wilson Boyles and Company, an international business consulting firm specializing in the development and implementation of successful business strategies. Prior to co-founding Wilson Boyles in 2003, she served as Senior Vice President for The Home Depot, having joined the company in 1998 following a 21-year career at Bank of America. Ms. Wilson was Executive Vice President of Bank of America as well as Chair and President of Security Pacific Financial Services, a wholly owned subsidiary of Bank of America. She sat on multiple corporate boards including The Home Depot, Farmers Insurance, IQHQ, and Sharp HealthCare. Various civic and philanthropic organizations benefited from Ms. Wilson’s generosity and acumen, and she served as a board member of many of San Diego’s leading civic organizations including San Diego Opera, The Civic Theater, the Museum of Contemporary Art San Diego, and the San Diego Humane Society.
The Biocept Board of Directors has appointed Bruce E. Gerhardt as Board Chair and Dr. Marsha A. Chandler as Board Vice Chair.
Mr. Gerhardt joined the Biocept Board in 2010. He has extensive experience and expertise in financial, accounting, and tax matters. He is a tax and business advisor for businesses and high net-worth individuals. Prior to joining Biocept, he was a financial vice-president with several companies and also previously worked for KPMG. He is a graduate of the University of Southern California and is a member of the American Institute of Certified Public Accountants.
Dr. Chandler joined the Biocept Board in 2013 and has extensive experience in organizational management and strategic initiatives, as well as significant stature in the life sciences community. She is Senior Vice Chancellor and Professor Emerita at the School of Global Policy and Strategy at the University of California, San Diego (UCSD). She currently serves as an Advisor to the College of GlobalHealth at Lehigh University, and the Jackson School of Geosciences as well as the College of Pharmaceutical Sciences at the University of Texas at Austin. Dr. Chandler is a member of the Board of Directors of the Corporate Directors Forum. She served as the Executive Vice-President and Chief Operating Officer of the Salk Institute for Biological Studies from 2007 to 2015. From 1997 to 2007 she was the Senior Vice Chancellor for Academic Affairs at UCSD. Dr. Chandler is a Fellow of the Royal Society of Canada. She received her Ph.D. from The University of North Carolina at Chapel Hill and has completed the Advanced Management Program at Harvard Business School.
About Biocept
Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. Our experts have spent years working to change the way physicians look at cerebrospinal fluid in cancer patients. Biocept has developed a unique, patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). As such, Biocept is a leading commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a cerebrospinal fluid sample.
